Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) and aging are locked in a vicious circle: ...

Aramchol, an SCD1 inhibitor, significantly attenuates and prevents biliary fibrosis in mouse models of primary sclerosing cholangitis (PSC) Aramchol treatment leads to significant inhibition (2 ...

Biomarkers at 6-week interim analysis show a positive impact on fibrogenesis, fibrolysis and potentially the initiation of a ...

IBEC researcher Juanma Fernández recently has received funding from the French AFM-Telethon to carry out the project “Monitoring of fibrotic processes in 3D skeletal muscle co-cultures for Muscular ...

Figure 2. FMT assay conditions have been optimized to ensure reproducibility and achieve the greatest assay window to allow the study of potential anti-fibrotic therapeutics.

Together with the robust anti-fibrotic effects of Aramchol previously demonstrated in clinical studies of patients with NASH and advanced fibrosis, these findings could potentially enable Galmed ...

Aramchol, an SCD1 inhibitor, significantly attenuates and prevents biliary fibrosis in mouse models of primary sclerosing cholangitis (PSC) Aramchol treatment leads to significant inhibition (2 ...